The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE^−/− Mice

Figure 7

The possible signal pathway of high glucose and high FFA activation NLRP3 inflammasome through ROS production and the possible interfering site of dapagliflozin.